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Abstract
Background: Fused heterocyclic 1,2,4-triazoles have acquired much importance because of their interesting biological
properties. Although a number of methods have been reported in the literature which includes oxidation with
phosphorus oxychloride, lead tetraacetate, bromine, etc., hypervalent iodine reagents have emerged as reagents of
choice for various synthetically useful transformations due to their low toxicity, ready availability and ease of handling.
Results: A series of new 3-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridines 4 has been conveniently
synthesized by oxidative cyclization of 2-(3-aryl-1-phenyl-1H-pyrazol-4-yl)methylene)-1-(pyridin-2-yl)hydrazines 3
promoted with iodobenzene diacetate under mild conditions (up to 90% isolated yields). All the new compounds
were tested in vitro for their antimicrobial activity.
Conclusions: Iodine(III)-mediated oxidative approach has offered an easy access to new 3-(3-aryl-1-phenyl-1H-
pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridines 4. The antibacterial and antifungal activities of newly synthesized
compounds have proved them potent antimicrobial agents.
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Background
Fused heterocyclic 1,2,4-triazoles have acquired much
importance because of their CNS depressant [1], antial-
lergy [2], antimicrobial [3] and anti-inflammatory [4]
properties. Most methods for the preparation of fused
1,2,4-triazole derivatives are based on the oxidation of
heterocyclic hydrazones or hydrazides with phosphorus
oxychloride [5], lead tetraacetate [5,6], bromine [6,7],
etc., which are associated with toxic properties. There-
fore, alternative approach avoiding these reagents is
always preferred.
Organohypervalent iodine reagents have emerged as
reagents of choice for various synthetically useful
transformations due to their low toxicity, ready availabil-
ity and ease of handling [8-17]. We have recently
reported the usefulness of iodobenzene diacetate (IBD)
to effect oxidative cyclization of benzalhydrazones to
1,2,4-triazoles [18-22].
Pyrazoles form an integral part of many natural pro-
ducts of therapeutic importance and possess potentially
reactive sites for a variety of chemical reactions to gen-
erate molecular diversity. (S)-3-Pyrazolylalanine [23],
lonazolac [24], difenamizole [25], mepirizole [26], meta-
mizol [27] and 4,5-dihydro-3-phenyl-6H-pyrrolo[1,2-b]
pyrazole are some of the biologically active compounds
endowed with antimicrobial [28], hypoglycaemic [29]
and non-nucleoside HIV-1 reverse transcriptase inhibi-
tor properties [30].
Our ongoing programme on the development of hyper-
valent iodine-mediated methodologies in heterocyclic
* Correspondence: dromprakash50@rediffmail.com
1Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra
136119, Haryana, India
Full list of author information is available at the end of the article
Prakash et al. Organic and Medicinal Chemistry Letters 2011, 1:1
http://www.orgmedchemlett.com/content/1/1/1
© 2011 Prakash et al; licensee Springer This is an Open Access article distributed under the terms of the Creative Commons Attribution
Licensesynthesis coupled with the significant biological impor-
tance of fused 1,2,4-triazole derivatives and pyrazole deri-
vatives, prompted us to undertake the synthesis of
hitherto unknown fused 1,2,4-triazolopyridines. We
report in this study on the synthesis of fused 3-(3-aryl-1-
phenyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridines 4
by the oxidation of 2-((3-aryl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-1-(pyridin-2-yl)hydrazines 3 using IBD in
dichloromethane with an expectation to find new and
more potent antibacterial and antifungal agents.
Results and discussion
Chemistry
First, we synthesized a series of 2-((3-aryl-1-phenyl-1H-
pyrazol-4-yl)methylene)-1-(pyridin-2-yl)hydrazines 3
needed for their oxidative cyclization. These substrates
were easily accessible in high yields (88-96%) and purity
from the reaction of 2-pyridyllhydrazine 1 and 3-aryl-1-
phenyl-1H-pyrazole-4-carbaldehydes 2 in ethanol
(Scheme 1) [31]. Then, the reaction of 2-((1,3-diphenyl-
1H-pyrazol-4-yl)methylene)-1-(pyridin-2-yl)hydrazine
(3a) (see Additional file 1) was carried out with 1.1
equivalents of IBD in dichloromethane by stirring at
room temperature overnight. The usual work-up of the
reaction afforded the expected product, 3-(1,3-diphenyl-
1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine (4a) (see
Additional file 2) in 90% yield (Scheme 1). To study the
scope of reaction, we carried out oxidation of a wide
range of substituted 2-((3-aryl-1-phenyl-1H-pyrazol-4-yl)
methylene)-1-(pyridin-2-yl)hydrazines (3b-g) (see Addi-
t i o n a lf i l e s3 ,4 ,5 ,6 ,7a n d8 )u n d e rs i m i l a rc o n d i t i o n s .
It was observed that IBD-mediated oxidative approach
worked nicely to give the desired products 4b-g (see
Additional files 9, 10, 11, 12, 13 and 14) in all cases in
82-90% yields.
The structures of all the compounds 3 and 4 were
confirmed by their spectral (IR,
1H NMR, Mass) and
elemental analytical data. For example, the IR spectrum
of the compound 3a exhibited characteristic absorption
band at 3190 cm
-1 due to NH functional group. The
1H
NMR spectrum of the product 3a showed two singlets
due to C(5)-H of pyrazole ring and N=CH at δ 8.93 and
δ 8.17, respectively, and also a broad singlet due to NH
at δ 10.66 which disappeared on the addition of D2O.
Other protons appeared as multiplet in the aromatic
regions. Mass spectrum of the compound 3a exhibited
molecular ion peak at m/z 340.06 [M + 1]
+.
The characterization of products 4 was based upon a
careful comparison of their IR and
1H NMR spectra
with those of 3.I Rs p e c t r ao f4 were found to be trans-
parent in the region of NH stretch, thus confirming the
oxidation of 3 into 4. An important characteristic fea-
ture in the
1H NMR spectra of 4 was the disappearance
of the singlet due to N=CH around δ 8.12-8.93, which
was present in the spectra of 3. The plausible mechan-
ism for the oxidation of 3 to 4 is analogous to our ear-
lier reports [18,19] and given in Scheme 2.
Pharmacology
In vitro antibacterial activity
All the synthesized compounds, 3a-g and 4a-g were
evaluated in vitro for their antibacterial activity against
two Gram-positive bacterial strains, Staphylococcus aur-
eus and Bacillus subtilis and two Gram-negative bacteria
namely, Escherichia coli and Pseudomonas aeruginosa,
and their activity was compared to a well-known com-
mercial antibiotic, ciprofloxacin. All the compounds
possessed variable antibacterial activity against Gram-
positive bacteria, S. aureus and B. subtilis.R e s u l t so f
antibacterial evaluation are summarized in Table 1 and
Figure 1. Compounds 3a-g and 4a-g showed zone of
inhibition ranging between 12.8 and 24.6 mm. On the
basis of zone of the inhibition produced against the test
bacteria, compound 3d was found to be the most effec-
tive against S. aureus and B. subtilis showing the maxi-
mum zone of inhibition of 18.6 and 19.3 mm,
respectively, when compared with commercial antibiotic
Scheme 1 Synthesis of title compound 4 via oxidation of 3. Ar:
Phenyl (a); 4-methylphenyl (b); 4-methoxyphenyl (c); 4-fluorophenyl
(d); 4-chlorophenyl (e); 4-bromophenyl (f); 4-nitrophenyl (g). Scheme 2 Mechanism for the oxidation of 3 to 4.
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tion of 27.6 and 26.3 mm against Gram-positive bac-
teria, S. aureus and B. subtilis, respectively. Compounds
4a, 4b, 4c and 4f were found to be the most effective
against both Gram-positive bacteria showing maximum
zone of inhibition ranging between 20.3 and 22.6 mm.
Rest of compounds showed fair activity against Gram-
positive bacterial strains (Table 1, Figure 1). All the
synthesized compounds showed fair activity against both
Gram-negative bacterial strains. In the whole series, the
MIC value of various synthesized compounds (3 and 4)
ranges between 16 and 256 μg/mL against Gram-posi-
tive and Gram-negative bacteria (Table 2, Figure 2). Out
of compounds 3a-3g,c o m p o u n d3d was found to be
the most effective against both Gram-positive bacteria
having the lowest MIC value 64 μg/mL when compared
with commercial antibiotic ciprofloxacin, which showed
MIC value 5 μg/mL for both Gram-positive bacteria.
Out of compounds 4a-4g, compounds 4a, 4b, 4c and 4f
possessed good antibacterial activity against B. subtilis
with MIC of 16, 16, 32 and 32 μg/mL, respectively
(Table 2, Figure 2).
In vitro antifungal activity
All the newly synthesized compounds (3 and 4) were
also tested in vitro for their antifungal activity against
two fungi, namely Aspergillus niger and Aspergillus fla-
vus. Standard antibiotic fluconazole was used for com-
parison with antifungal activity shown by compounds
3a-g and 4a-g. A careful analysis of percentage myce-
lial growth inhibition revealed that compounds 3a, 3b,
3c and 3d exhibit good antifungal activity against both
A. flavus and A. niger. Out of compounds 4a-g,
Table 1 In vitro antibacterial activity of compounds 3 and 4
Compounds Diameter of growth of inhibition zone (mm)
a
Staphylococcus aureus Bacillus subtilis Escherichia coli Pseudomonas aeruginosa
3a 17.3 19.3 13.3 15.6
3b 16.6 17.3 - 13.2
3c 17.3 18.6 13.0 12.8
3d 18.6 19.3 14.3 15.0
3e 16.3 17.6 14.2 -
3f 16.3 17.6 - 13.5
3g 17.0 18.3 13.8 14.3
4a 22.6 24.6 19.6 17.3
4b 21.3 24.6 18.0 16.6
4c 20.3 21.6 16.3 15.3
4d 17.0 18.6 15.6 13.6
4e 15.5 16.0 - 16.2
4f 21.6 22.6 17.3 15.6
4g 18.6 19.3 14.6 15.3
Ciprofloxacin 27.6 26.3 25.0 25.3
-, no activity
aValues including diameter of the well (8 mm), are means of three replicates
Figure 1 Comparison of diameter of growth of inhibition of compounds (3 and 4) and standard drug.
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Page 3 of 9compounds 4a, 4b, 4c and 4f showed excellent activity
against both antifungal strains as shown in Table 3
and Figure 3. It indicates that fused triazoles 4a-g con-
taining electron-releasing substituents (4a, 4b and 4c)
at para position of aryl ring of pyrazole moiety are
more antifungal than triazoles having electron-with-
drawing groups (4d, 4e, 4f and 4g)a tt h es a m e
position.
A careful analysis of MIC data revealed some interest-
ing results (Table 2) which are as follows
(i) Compounds 3a-g have shown marginal activity,
but after oxidative cyclization of these compounds, it
was found that antibacterial activity has been
increased.
(ii) Inhibitory data of compounds 4a-g suggested
that the replacement of para proton of aryl ring of
pyrazole moiety (at 3-position) in 3-(3-aryl-1-phenyl-
1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridines (4a-g)
with electron-releasing groups the antibacterial activ-
ity increases while replacing the same aryl proton
with electron-withdrawing group the antibacterial
activity decreases. In compound 4b,t h ep r o t o na t
para position of aryl ring of pyrazole moiety is
replaced with methyl group, and in compound 4c,
the proton at para position of aryl ring of pyrazole
moiety is replaced with methoxy group, both of
these compounds exhibited significant level of anti-
bacterial activity. Compounds 4d, 4e, 4f (containing
halogen at para position of aryl ring of pyrazole
Table 2 Minimum inhibitory concentration (μg/mL) of compounds 3 and 4
Compounds Minimum inhibitory concentration (μg/mL)
Staphylococcus aureus Bacillus subtilis Escherichia coli Pseudomonas aeruginosa
3a 128 64 256 128
3b 128 128 NT 256
3c 128 64 256 256
3d 64 64 256 256
3e 128 128 256 NT
3f 128 128 NT 256
3g 128 64 256 256
4a 32 16 64 64
4b 32 16 64 128
4c 64 32 128 128
4d 128 64 128 256
4e 128 128 256 128
4f 32 32 64 128
4g 64 64 256 256
Ciprofloxacin 5 5 5 5
NT, not tested.
Figure 2 Comparison of MIC of compounds (3 and 4) and standard drug.
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tion of aryl ring of pyrazole moiety) have shown
marginal activities against all four bacteria.
Conclusions
We have described in this study an efficient and conve-
nient synthesis of some new 3-(3-aryl-1-phenyl-1H-pyra-
zol-4-yl)-[1,2,4]triazolo[4,3-a]pyridines (4a-g) via the
oxidative cyclization of hydrazones 3, thereby emphasiz-
ing the increasing utility of hypervalent iodine(III)-
mediated methods. The antibacterial and antifungal
activities of newly synthesized compounds 3 and 4 have
proven them potent antibacterial and antifungal agents.
Compounds 3a-3g have shown marginal activity. Inhibi-
tory data of compounds 4a-4g suggested that by the repla-
cement of para proton of aryl ring of pyrazole moiety in
3-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]
pyridines (4a-g) with electron-releasing groups the anti-
bacterial activity increased while as the para proton of aryl
ring of pyrazole moiety is replaced with electron-with-
drawing group, the antibacterial activity decreases.
Triazoles 4 having electron-releasing substituents at
para position of aryl ring of pyrazole moiety (4a, 4b and
4c) are more antifungal than triazoles containing elec-
tron-withdrawing groups (4a, 4e, 4f and 4g) at the same
position.
Experimental
Melting points were taken on slides in an electrical
apparatus Labindia visual melting range apparatus and
a r eu n c o r r e c t e d .T h eI Rs p e c t r aw e r eo b t a i n e dw i t ha
Buck Scientific IR M-500 spectrophotometer. The
1H
NMR spectra were recorded on a Bruker (300 MHz)
spectrometer using tetramethylsilane as an internal stan-
dard. All the compounds gave satisfactory analytical
results (within 0.4% of the theoretical values). The start-
ing material 4-formylpyrazoles 2 were prepared by the
literature method [32].
2-((3-Aryl-1-phenyl-1H-pyrazol-4-yl)methylene)-1-(pyridin-
2-yl)hydrazines (3)
General procedure: To the ethanolic solution of 2-pyri-
dylhydrazine (1, 0.01 mol) was added appropriate 4-for-
mylpyrazole (2, 0.01 mol), and the solution was refluxed
for 4-5 min. The solvent was evaporated in vacuo to
half its volume and cooled to room temperature. The
solid obtained was filtered and washed with ethanol.
2-((1,3-Diphenyl-1H-pyrazol-4-yl)methylene)-1-(pyridin-2-
yl)hydrazine (3a)
Y i e l d9 6 % ,M p2 1 0 ° C ,I R( νmax, KBr): 3190 cm
-1 (-NH
str.);
1H NMR (DMSO-d6, 300 MHz): δ 6.71-6.74 (m,
1H), 7.18-7.21 (m, 1H, J = 9 Hz), 7.34-7.39 (m, 1H),
7.47-7.63 (m, 6H), 7.74-7.77 (m, 2H), 7.98-8.01 (m, 2H),
8.07-8.09 (d, 1H, J = 6 Hz), 8.17(s, 1H, N=CH), 8.93(s,
Table 3 In vitro antifungal activity of compounds 3 and 4
Compounds Mycelial growth of inhibition (%)
Aspergillus niger Aspergillus flavus
3a 52.5 51.1
3b 51.1 50.6
3c 52.5 51.1
3d 50.0 49.8
3e 44.4 45.5
3f 45.5 44.4
3g 47.7 45.5
4a 66.5 58.8
4b 62.3 62.5
4c 60.5 60.6
4d 52.5 51.1
4e 48.8 50.0
4f 69.5 68.5
4g 51.1 50.0
Fluconazole 81.1 77.7
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Figure 3 Comparison of antifungal activity of compounds (3 and 4) and standard drug.
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Page 5 of 91H), 10.66 (bs, 1H, exchangeable with D2O); Anal. Cal-
culated for C21H17N5: C 74.32, H 5.05, N 20.63; Found:
C 74.35, H 5.04, N 20.64; ESI-MS m/z: 340.06 [M + 1]
+.
2-((1-Phenyl-3-p-tolyl-1H-pyrazol-4-yl)methylene)-1-
(pyridin-2-yl)hydrazine (3b)
Y i e l d9 4 % ,M p2 0 6 ° C ,I R( νmax, KBr): 3194 cm
-1 (-NH
str.);
1H NMR (DMSO-d6,3 0 0M H z ) :δ 2.40 (s, 3H),
6.73-6.74 (m, 1H), 7.20-7.23 (d, 1H, J = 9 Hz), 7.32-7.38
(m, 3H), 7.51-7.59 (d, 2H, J = 9 Hz), 7.62-7.65 (m, 3H),
7.98-8.09 (m, 3H), 8.15 (s, 1H), 8.93(s, 1H, N=CH),
10.69 (bs, 1H, exchangeable with D2O); Anal. Calculated
for C22H19N5: C 74.77, H 5.42, N 19.82; Found: C 74.79,
H 5.45, N 19.79; ESI-MS m/z: 354.12 [M + 1]
+
2-((3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-1-(pyridin-2-yl)hydrazine (3c)
Y i e l d8 9 % ,M p2 0 8 ° C ,I R( νmax, KBr): 3189 cm
-1 (-NH
str.);
1HN M R( D M S O - d6, 300 MHz): δ 3.84(s, 3H),
6.70-6.74 (m, 1H), 7.07-7.10 (d, 2H, J = 9 Hz), 7.19-7.22
(m, 1H), 7.45-7.38 (m, 1H), 7.51-7.64 (m, 3H), 7.67-7.70
(d, 2H, J = 9 Hz), 7.97-8.00 (m, 2H), 8.07-8.09 (d, 1H, J
= 6 Hz), 8.14 (s, 1H, N=CH), 8.91(s, 1H), 10.67 (bs, 1H,
exchangeable with D2O); Anal. Calculated for
C22H19N5O: C 71.53, H 5.18, N 18.96; Found: C 71.53,
H 5.20, N 18.92; ESI-MS m/z: 370.08 [M + 1]
+.
2-((3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-1-(pyridin-2-yl)hydrazine (3d)
Yield 90%, Mp 224°C, IR (νmax, KBr): 3198 cm
-1 (-NH str.);
1H NMR (DMSO-d6, 300 MHz): δ 6.71-6.75 (m, 1H), 7.14-
7.17 (m, 1H), 7.33-7.39 (m, 3H), 7.52-7.63 (m, 3H), 7.79-
7.84 (d, 2H, J = 9 Hz), 7.97-8.00 (d, 2H, J = 9 Hz), 8.08-
8.09 (d, 1H, J = 3 Hz), 8.15 (s, 1H, N=CH), 8.93 (s, 1H),
10.66 (bs, 1H, exchangeable with D2O); Anal. Calculated
for C21H16FN5: C 70.58, H 4.51, N 19.60; Found: C 70.59,
H 4.53, N 19.58; ESI-MS m/z: 358.10 [M + 1]
+.
2-((3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-1-(pyridin-2-yl)hydrazine (3e)
Y i e l d9 0 % ,M p2 3 2 ° C ,I R( νmax, KBr): 3200 cm
-1 (-NH
str.);
1H NMR (DMSO-d6, 300 MHz): δ 6.70-6.74 (m,
1H), 7.13-7.15 (m, 1H), 7.34-7.39 (m, 1H), 7.52-7.62 (m,
5H), 7.79-7.82 (d, 2H, J = 9 Hz), 7.96-7.99 (d, 2H, J =9
Hz), 8.07-8.09 (d, 1H, J = 6 Hz), 8.15 (s, 1H, N=CH),
8.91 (s, 1H), 10.64 (bs, 1H, exchangeable with D2O);
Anal. Calculated for C21H16ClN5: C 67.47, H 4.31, N
18.73; Found: C 67.41, H 4.30, N 18.75; ESI-MS m/z:
374.10 [M + 1]
+, 376.10 [M + 3]
+.
2-((3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)
methylene)-1-(pyridin-2-yl)hydrazine (3f)
Yield 91%, Mp 236°C, IR (νmax, in KBr): 3203 cm
-1 (-NH
str.);
1H NMR (DMSO-d6, 300 MHz): δ 6.69-6.73 (m,
1H), 7.12-7.14 (m, 1H), 7.35-7.38 (m, 1H), 7.50-7.59 (m,
3H), 7.71 (m, 4H), 7.95-7.98 (d, 2H, J = 8.1 Hz), 8.06-
8.07 (d, 1H, J = 4.5 Hz), 8.12 (s, 1H, N=CH), 8.93(s,
1H), 10.67 (bs, 1H, exchangeable with D2O); Anal. Cal-
culated for C21H16BrN5: C 60.30, H 3.86, N 16.74;
Found: C 60.28, H 3.83, N 16.77; ESI-MS m/z:3 8 5 . 1 2
([M + 1]
+, 387.02 [M + 3]
+.
2-((3-(4-Nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-
1-(pyridin-2-yl)hydrazine (3g)
Yield 92%, Mp 234°C, IR (νmax, in KBr): 3195 cm
-1 (-NH
str.) 1335, 1504 (-NO2);
1H NMR (DMSO-d6, 300
MHz): δ 6.72-6.76 (m, 1H), 7.12-7.15 (m, 1H), 7.38-7.42
(m, 1H), 7.54-7.63 (m, 3H), 8.00-8.03 (m, 2H, J = 9 Hz),
8.08-8.11 (m, 3H), 8.20 (s, 1H, N=CH), 8.36-8.39 (d, 2H,
J = 9 Hz), 9.01 (s, 1H), 10.76 (bs, 1H, exchangeable with
D2O); Anal. Calculated for C21H16N6O2:C6 5 . 6 2 ,H
4.20, N 21.86; Found: C 65.64, H 4.26, N 21.85; ESI-MS
m/z: 267.06 [M + 1]
+.
Synthesis of 3-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-[1,2,4]
triazolo[4,3-a]pyridines (4)
General procedure: To a suspension/solution of 3
(0.010 mol) in dichloromethane (25 mL), IBD (0.011
mol) was added in small portions, and the reaction
mixture was stirred overnight. Then, the solvent was
evaporated on water bath. To the resulting residue was
added ethanol (5-10 mL), and the mixture was warmed
to obtain a clear solution. On cooling at room tem-
perature, solid separated out was filtered and washed
with cold alcohol to give pure fused 1,2,4-triazole deri-
vatives 4a-g.
(1,3-Diphenyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine
(4a)
Yield 90%, Mp 162°C, IR (νmax, KBr): transparent in
the region of -NH str.;
1H NMR (DMSO-d6,3 0 0
MHz): δ 6.89-6.94 (m, 1H), 7.33-7.35 (m, 3H), 7.38-
7.45 (m, 2H), 7.54-7.63 (m, 4H), 7.84-7.87 (s, 1H),
7.99-8.05 (m, 2H), 8.15-8.17 (d, 1H, J = 6 Hz), 9.16 (s,
1H); Anal. Calculated for C21H15N5: C 74.76, H 4.48,
N 20.76; Found: C 74.77, H 4.45, N 20.73; ESI-MS m/
z: 338.09 [M + 1]
+.
3-(1-Phenyl-3-p-tolyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]
pyridine (4b)
Yield 88%, Mp 210°C, IR (νmax, KBr): transparent in the
region of -NH str.;
1H NMR (DMSO-d6,3 0 0M H z ) :δ
2.28 (s, 3H) 6.89-6.93 (m, 1H), 7.13-7.16 (m, 2H), 7.38-
7.44 (m, 4H), 7.57-7.62 (m, 2H), 7.80-7.84 (m, 1H),
8.01-8.03 (d, 2H, J = 6 Hz), 8.12-8.14 (d, 1H, J =6H z ) ,
9.13 (s, 1H); Anal. Calculated for C22H17N5: C 75.19, H
4.88, N 19.93; Found: C 75.18, H 4.86, N 19.96; ESI-MS
m/z: 352.11 [M + 1]
+.
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Page 6 of 93-(3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-[1,2,4]
triazolo[4,3-a]pyridine (4c)
Yield 82%, Mp 164°C, IR (νmax, KBr): transparent in the
region of -NH str.;
1H NMR (DMSO-d6,3 0 0M H z ) :δ
3.73 (s, 3H) 6.89-6.94 (m, 3H), 7.36-7.40 (m, 2H), 7.47-
7.49 (m, 2H), 7.56-7.61 (m, 2H), 7.80-7.87 (m, 1H),
7.95-8.02 (m, 2H), 8.14-8.16 (m, 1H), 9.12 (s, 1H); Anal.
Calculated for C22H17N5O: C 71.92, H 4.66, N 19.06;
Found: C 71.91, H 4.64, N 19.07; ESI-MS m/z:3 6 8 . 0 6
[M + 1]
+.
3-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-[1,2,4]
triazolo[4,3-a]pyridine (4d)
Yield 85%, Mp 193°C, IR (νmax, KBr): transparent in the
region of -NH st.;
1H NMR (DMSO-d6, 300 MHz): δ
6.92-6.97 (m, 1H), 7.17-7.23 (m, 2H), 7.39-7.44 (m, 2H),
7.57-7.68 (m, 4H), 7.85-7.88 (m, 1H), 8.02-8.05 (d, 2H, J
= 9 Hz), 8.24-8.26 (d, 1H, J = 6 Hz), 9.19 (s, 1H); Anal.
Calculated for C21H14FN5: C 70.98, H 3.97, N 19.71;
Found: C 70.98, H 3.99, N 19.69; ESI-MS m/z:3 5 6 . 0 8
[M + 1]
+.
3-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-[1,2,4]
triazolo[4,3-a]pyridine (4e)
Yield 89%, Mp 133°C, IR (νmax, KBr): transparent in the
region of -NH str.;
1H NMR (DMSO-d6,3 0 0M H z ) :δ
6.93-6.98 (m, 1H), 7.41-7.45 (m, 4H), 7.57-7.64 (m, 4H),
7.85-7.88 (m, 1H), 8.02-8.04 (d, 2H, J = 6 Hz), 8.25-8.27
(d, 1H, J = 6 Hz), 9.19 (s, 1H); Anal. Calculated for
C21H14ClN5: C 67.83, H 3.80, N 18.84; Found: C 67.81,
H 3.84, N 18.80; ESI-MS m/z: 372.01 [M + 1]
+, 374.06
[M + 3]
+.
3-(3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)-[1,2,4]
triazolo[4,3-a]pyridine (4f)
Yield 84%, Mp 140°C, IR (νmax, KBr): transparent in the
region of -NH str.;
1H NMR (DMSO-d6,3 0 0M H z ) :δ
6.92-6.96 (m, 1H), 7.38-7.43 (m, 2H), 7.54-7.60 (m, 6H),
7.83-7.86 (m, 1H), 7.99-8.02 (d, 2H, J = 8.1 Hz), 8.23-
8.26 (d, 1H, J = 6.9 Hz), 9.17 (s, 1H); Anal. Calculated
for C21H14BrN5: C 60.59, H 3.39, N 16.82; Found: C
60.56, H 3.37, N 16.81; ESI-MS m/z:4 1 6 . 0 4[ M+1 ]
+,
418.06 [M + 3]
+.
3-(3-(4-Nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-[1,2,4]
triazolo[4,3-a]pyridine (4g)
Yield 89%, Mp 242°C, IR (νmax, KBr): transparent in the
region of -NH str.;
1H NMR (DMSO-d6,3 0 0M H z ) :δ
6.82-6.86 (m, 1H), 7.34-7.41 (m, 1H), 7.44-7.46 (m, 1H),
7.55-7.60 (m, 3H), 7.83-7.87 (m, 3H), 7.92-7.94 (d, 2H, J
= 6 Hz), 8.14-8.17 (d, 2H, J = 9 Hz), 8.71 (s, 1H); Anal.
Calculated for C21H14N6O2: C 65.96, H 3.69, N 21.98;
Found: C 65.97, H 3.67, N 21.94; ESI-MS m/z:3 8 3 . 1 0
[M + 1]
+.
Biological assay
Test microorganisms
Total six microbial strains were selected on the basis of
their clinical importance in causing diseases in humans.
Two Gram-positive bacteria (Staphylococcus aureus
MTCC 96 and Bacillus subtilis MTCC 121); two Gram-
negative bacteria (Escherichia coli MTCC 1652 and
Pseudomonas aeruginosa MTCC 741) and two fungi,
Aspergillus niger and A. flavus,t h ee a rp a t h o g e n si s o -
lated from the patients of Kurukshetra, were used in the
present study for the evaluation of antimicrobial activity
of the compounds [33]. All the cultures were procured
from Microbial Type Culture Collection (MTCC),
IMTECH, Chandigarh. The bacteria were subcultured
on nutrient agar, whereas fungi on Sabouraud dextrose.
In vitro antibacterial activity
The antibacterial activity of chemical compounds was
evaluated by the agar well diffusion method. All the cul-
tures were adjusted to 0.5 McFarland standards, which
is visually comparable to a microbial suspension of
approximately 1.5 × 10
8 cfu/mL. 20 mL of Mueller Hin-
ton agar medium was poured into each Petri plate, and
the agar plates were swabbed with 100 μLi n o c u l ao f
each test bacterium and kept for 15 min for adsorption.
Using sterile cork borer of 8 mm diameter, wells were
bored into the seeded agar plates, and these were loaded
with a 100 μL volume with concentration of 2.0 mg/mL
of each compound reconstituted in the dimethylsulph-
oxide (DMSO). All the plates were incubated at 37°C
for 24 h. Antibacterial activity of each compound was
e v a l u a t e db ym e a s u r i n gt h ez o n eo fg r o w t hi n h i b i t i o n
against the test organisms with zone reader (Hi Antibio-
t i cz o n es c a l e ) .T h eD M S Ow a su s e da san e g a t i v ec o n -
trol, whereas ciprofloxacin was used as a positive
control. This procedure was performed in three replicate
plates for each organism [34].
Determination of minimum inhibitory
concentration (MIC)
The MIC is the lowest concentration of an antimicrobial
compound that will inhibit the visible growth of a
microorganism after overnight incubation. The MIC of
all the synthesized compounds (3 and 4) against bacter-
ial strains was tested through a modified agar well-diffu-
sion method [35]. In this method, a twofold serial
dilution of each compound was prepared by first recon-
stituting the compound in DMSO followed by dilution
in sterile, distilled water to achieve a decreasing concen-
tration range of 256-0.5 μg/mL. A 100 μLv o l u m eo f
each dilution was introduced into wells (in triplicate) in
the agar plates already seeded with 100 μLo fs t a n d a r -
dized inoculum (10
6 cfu/mL) of the test microbial strain.
All test plates were incubated aerobically at 37°C for 24
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as the lowest concentration of the chemical compound
that completely inhibited the growth of the microbe,
showed by a clear zone of inhibition, was recorded for
each test organism. Ciprofloxacin was used as positive
control while DMSO as negative control.
In vitro antifungal activity
T h ea n t i f u n g a la c t i v i t yo ft h en e w l ys y n t h e s i z e dc o m -
pounds was evaluated by poison food technique. The
moulds were grown on Sabouraud dextrose agar (SDA)
at 25°C for 7 days and used as inocula. 15 mL of molten
SDA (45°C) was poisoned by the addition of 100 μL
volume of each compound having concentration of 4.0
mg/mL, reconstituted in the DMSO, poured into a ster-
ile Petri plate and allowed to solidify at room tempera-
ture. The solidified poisoned agar plates were inoculated
at the centre with fungal plugs (8 mm diameter),
obtained from the actively growing colony and incu-
bated at 25°C for 7 days. The DMSO was used as the
negative control, whereas fluconazole was used as the
positive control. The experiments were performed in tri-
plicates. Diameter of the fungal colonies was measured
and expressed as percent mycelial inhibition determined
by applying the following formula [36]:
dc, average diameter of fungal colony in negative con-
trol plates; dt average diameter of fungal colony in
experimental plates.
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